{
    "data": [
        {
            "id": "4659348",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-23T08:30:00-05:00",
                "isLockedPro": false,
                "commentCount": 54,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1411239127/image_1411239127.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "511017",
                            "type": "sentiment"
                        },
                        {
                            "id": "511234",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4659348-eli-lilly-consider-cutting-before-the-southbound-train-leaves-rating-downgrade"
            }
        },
        {
            "id": "4659097",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-21T17:34:44-05:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/521503314/image_521503314.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: Long Path To A Trillion",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "510864",
                            "type": "sentiment"
                        },
                        {
                            "id": "510961",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4659097-eli-lilly-long-path-to-a-trillion"
            }
        },
        {
            "id": "4655016",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-30T11:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 27,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1453534485/image_1453534485.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105218",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "505203",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4655016-eli-lilly-bubble-warning-unrealistic-growth-and-multiple-risk-factors"
            }
        },
        {
            "id": "4652291",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-16T06:19:09-05:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1414474713/image_1414474713.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: Perfectly Priced Healthcare Giant",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104695",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "502212",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4652291-eli-lilly-perfectly-priced-healthcare-giant"
            }
        },
        {
            "id": "4651116",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-13T03:22:32-05:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1756469701/image_1756469701.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: Favorable Developments Continue Regarding Anti-Obesity Drug Franchise",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71565",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "501579",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4651116-eli-lilly-favorable-developments-continue-regarding-anti-obesity-drug-franchise"
            }
        },
        {
            "id": "4650257",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-10T02:43:44-05:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1442514122/image_1442514122.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: Zepbound FDA Approval Is A Sell-The-News Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104812",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "500813",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4650257-eli-lilly-earnings-zepbound-fda-approval-sell-news-opportunity"
            }
        },
        {
            "id": "4649863",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-09T13:43:19-05:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/521503314/image_521503314.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly's Big Win In The Obesity Space Just Got Bigger",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "69675",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "500775",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4649863-eli-lilly-big-win-in-the-obesity-space-just-got-bigger"
            }
        },
        {
            "id": "4649750",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-09T11:22:45-05:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1152774435/image_1152774435.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: Zepbound For Weight Loss FDA Approved - Time To Believe The Hype?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "500703",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4649750-eli-lilly-stock-zepbound-weight-loss-drug-fda-approved"
            }
        },
        {
            "id": "4644385",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-30T07:05:00-04:00",
                "isLockedPro": false,
                "commentCount": 125,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1300171618/image_1300171618.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Albemarle Vs. Eli Lilly: 1 Potentially Set To Soar And 1 Bubble Stock To Ignore",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "496494",
                            "type": "sentiment"
                        },
                        {
                            "id": "496495",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4644385-albemarle-vs-eli-lilly-1-potentially-set-to-soar-and-1-bubble-stock-to-ignore"
            }
        },
        {
            "id": "4640279",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-11T17:33:21-04:00",
                "isLockedPro": false,
                "commentCount": 134,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1465020733/image_1465020733.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71565",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "492783",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4640279-eli-lilly-glp-one-opportunity-while-increasingly-recognized-is-vastly-underestimated"
            }
        },
        {
            "id": "4638867",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-06T14:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1297197364/image_1297197364.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: Do Not Chase This Stock Over The Cliff",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106485",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "490636",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4638867-eli-lilly-do-not-chase-this-stock-over-cliff"
            }
        },
        {
            "id": "4639088",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-05T02:41:08-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1414474713/image_1414474713.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: Big Cancer Bet With Point Biopharma Global Purchase",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "69675",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "491103",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4639088-eli-lilly-big-cancer-bet-with-point-biopharma-global-purchase"
            }
        },
        {
            "id": "4638761",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-03T13:32:22-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/113121982/image_113121982.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly POINTs Toward Radiopharmaceutical Ambitions",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103833",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "490689",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4638761-eli-lilly-point-biopharma-deal-radiopharmaceutical-ambitions"
            }
        },
        {
            "id": "4636197",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-20T12:30:00-04:00",
                "isLockedPro": false,
                "commentCount": 20,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1318526353/image_1318526353.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: Don't Be Fooled By Greed",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "487178",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4636197-eli-lilly-stock-dont-be-fooled-maintain-hold"
            }
        },
        {
            "id": "4635062",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-13T23:19:53-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1467665258/image_1467665258.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: A Potential Game Changer For Weight Management And Cardiovascular Health",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "52852",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "485382",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4635062-eli-lilly-a-potential-game-changer-for-weight-management-and-cardiovascular-health"
            }
        },
        {
            "id": "4634349",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-11T12:07:11-04:00",
                "isLockedPro": false,
                "commentCount": 49,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1414474713/image_1414474713.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly Stock Hits New All-Time Highs: Is It Still A Buy?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24634",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "484891",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4634349-eli-lilly-stock-hits-new-all-time-high-is-lly-still-buy"
            }
        },
        {
            "id": "4630848",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-24T11:27:41-04:00",
                "isLockedPro": false,
                "commentCount": 60,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1393991950/image_1393991950.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly And Novo Nordisk: Are Weight Loss Drugs A Global Revolution Or Short-Lived Fad?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20642",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "480548",
                            "type": "sentiment"
                        },
                        {
                            "id": "480549",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4630848-eli-lilly-novo-nordisk-weight-loss-drugs-global-revolution-short-lived-fad"
            }
        },
        {
            "id": "4630311",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-23T07:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 82,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1257928604/image_1257928604.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Sell Eli Lilly And Buy This Coiled-Spring Dividend Aristocrat Instead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "480140",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4630311-sell-eli-lilly-and-buy-this-coiled-spring-dividend-aristocrat-instead"
            }
        },
        {
            "id": "4628266",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-14T14:43:21-04:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1318526353/image_1318526353.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly Q2: Dividends Don't Lie",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "478125",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4628266-eli-lilly-q2-dividends-dont-lie"
            }
        },
        {
            "id": "4625480",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-08T14:45:47-04:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386988615/image_1386988615.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: Q2 And 2023 Revised Guidance Impressive, But Key Is Wegovy Data",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71565",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "476731",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4625480-eli-lilly-q2-and-2023-revised-guidance-impressive-but-key-is-wegovy-data"
            }
        },
        {
            "id": "4625426",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-08T13:05:05-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1598420812/image_1598420812.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly Remains A Buy With Strong Sales And Possible Upside With Mounjaro",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "476743",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4625426-eli-lilly-remains-a-buy-with-strong-sales-and-possible-upside-with-mounjaro"
            }
        },
        {
            "id": "4621929",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-31T18:26:24-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/521503314/image_521503314.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Inside Eli Lilly's Strategic Investment In Sigilon: An Opportunity Overlooked",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "474640",
                            "type": "sentiment"
                        },
                        {
                            "id": "474641",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4621929-inside-eli-lillys-strategic-investment-in-sigilon-an-opportunity-overlooked"
            }
        },
        {
            "id": "4619944",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-28T16:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/185410983/image_185410983.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: There Is No Logic To This Over Optimism",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106485",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "473188",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4619944-eli-lilly-there-is-no-logic-to-this-over-optimism"
            }
        },
        {
            "id": "4619503",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-25T10:22:46-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1368821405/image_1368821405.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen, Eisai, And Eli Lilly: Goldilocks-Like Treatments For Alzheimer's May Hurt",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "97526",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "472828",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4619503-biogen-eisai-and-eli-lilly-goldilocks-like-treatments-for-alzheimers-may-hurt"
            }
        },
        {
            "id": "4619260",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-24T15:08:24-04:00",
                "isLockedPro": false,
                "commentCount": 27,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/933896402/image_933896402.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: Does 'Miracle' Weight Loss Franchise Justify Rising Price Tag?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "472987",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4619260-eli-lilly-does-miracle-weight-loss-franchise-justify-rising-price-tag"
            }
        },
        {
            "id": "4617956",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-18T22:05:00-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1411734128/image_1411734128.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Lilly's Alzheimer's Data For Donanemab",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20694",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4617956-eli-lilly-alzheimers-data-for-donanemab"
            }
        },
        {
            "id": "4616389",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-11T15:42:11-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1291258680/image_1291258680.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly And Company Has Many Catalysts",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "75375",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "469681",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4616389-eli-lilly-and-company-has-many-catalysts"
            }
        },
        {
            "id": "4616021",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-10T04:49:51-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1318526353/image_1318526353.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: Patients Get Skinnier, Profits Get Fatter",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "469143",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4616021-eli-lilly-patients-get-skinnier-profits-get-fatter"
            }
        },
        {
            "id": "4615981",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-09T22:42:12-04:00",
                "isLockedPro": false,
                "commentCount": 40,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1414474713/image_1414474713.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: The Party Is Likely Over",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "469237",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4615981-eli-lilly-stock-potential-near-term-volatility-hold"
            }
        },
        {
            "id": "4614721",
            "type": "article",
            "attributes": {
                "publishOn": "2023-06-30T22:23:44-04:00",
                "isLockedPro": false,
                "commentCount": 40,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1414474713/image_1414474713.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: Miracle Drug Progress Offers Shareholders More Upside",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "69675",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "467591",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4614721-eli-lilly-lly-miracle-drug-progress-offers-shareholders-more-upside"
            }
        },
        {
            "id": "4610289",
            "type": "article",
            "attributes": {
                "publishOn": "2023-06-08T10:45:18-04:00",
                "isLockedPro": false,
                "commentCount": 35,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1271490921/image_1271490921.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: Most Valuable Global Pharma Thanks To Tirzepatide's Mind-Blowing Possibilities",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "462137",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4610289-eli-lilly-most-valuable-global-pharma-tirzepatides-possibilities"
            }
        },
        {
            "id": "4610182",
            "type": "article",
            "attributes": {
                "publishOn": "2023-06-08T02:27:51-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1426368585/image_1426368585.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: Balancing Innovation And Valuation In A Changing Landscape",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103833",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "461426",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4610182-eli-lilly-stock-balancing-innovation-valuation-changing-landscape-hold"
            }
        },
        {
            "id": "4601448",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-08T05:28:36-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1406643068/image_1406643068.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "DICE Therapeutics: Worth A Roll At The Right Price",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "454624",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4601448-dice-therapeutics-worth-a-roll-at-the-right-price"
            }
        },
        {
            "id": "4600816",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-06T01:58:52-04:00",
                "isLockedPro": false,
                "commentCount": 49,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/92003014/image_92003014.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly's Donanemab: The Anti-Amyloid Saga Continues",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "97526",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "454236",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4600816-eli-lillys-donanemab-the-anti-amyloid-saga-continues"
            }
        },
        {
            "id": "4599880",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-04T10:55:34-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962527/image_1386962527.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly's Alzheimer's Breakthrough: A Game Changer For Investors And Patients",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "52852",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "453966",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4599880-eli-lilly-alzheimers-breakthrough-game-changer-investors-patients"
            }
        },
        {
            "id": "4599679",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-03T22:35:00-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1414474713/image_1414474713.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Lilly's New Donanemab Data For Alzheimer's",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20694",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4599679-eli-lilly-new-donanemab-data-for-alzheimers"
            }
        },
        {
            "id": "4596089",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-24T15:46:34-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1318526353/image_1318526353.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly Q1 2023 Earnings Preview: Mounjaro Sales Will Be The Headline News",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "451853",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4596089-eli-lilly-q1-earnings-preview-mounjaro-sales-headline-news"
            }
        },
        {
            "id": "4594060",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-14T05:29:16-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1387838599/image_1387838599.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: Skinny Customers, Fat Profits",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "52852",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "449813",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4594060-eli-lilly-stock-strong-pipeline-compelling-investment-opportunity"
            }
        },
        {
            "id": "4589465",
            "type": "article",
            "attributes": {
                "publishOn": "2023-03-23T00:32:32-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: Best-Now Near-Term Price Gains Pharmaceuticals Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23468",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "445484",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4589465-eli-lilly-best-now-near-term-price-gains-pharmaceuticals-stock"
            }
        },
        {
            "id": "4579609",
            "type": "article",
            "attributes": {
                "publishOn": "2023-02-17T16:32:14-05:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1411734128/image_1411734128.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly Is Still Overvalued But Should Be On Your Watchlist",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80836",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "438532",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4579609-eli-lilly-is-still-overvalued-but-should-be-on-your-watchlist"
            }
        },
        {
            "id": "4579573",
            "type": "article",
            "attributes": {
                "publishOn": "2023-02-17T14:46:46-05:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1410104734/image_1410104734.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: Mounjaro Needs To Catch Up In 2023",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "75375",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "438517",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4579573-eli-lilly-mounjaro-needs-to-catch-up-in-2023"
            }
        },
        {
            "id": "4572331",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-25T14:12:05-05:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1291258680/image_1291258680.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: Far From Dead In Alzheimer's, But Needs Help From Other Areas",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "75375",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "433551",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4572331-eli-lilly-far-from-dead-in-alzheimers-but-needs-help-from-other-areas"
            }
        },
        {
            "id": "4572136",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-25T00:38:53-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1257405518/image_1257405518.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "DICE Therapeutics: Risks To Reversal Rally Noted In Market Data (Technical Analysis)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105793",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "433174",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4572136-dice-therapeutics-risks-to-reversal-rally-noted-in-market-data-technical-analysis"
            }
        },
        {
            "id": "4571853",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-24T04:41:30-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "DICE Therapeutics: Oral Drug Of Proven IL-17 Target",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "433190",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4571853-dice-therapeutics-oral-drug-of-proven-il-17-target"
            }
        },
        {
            "id": "4569436",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-12T03:27:27-05:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1276669617/image_1276669617.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly: Bears May Be Making A Huge Mistake",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "430903",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1421",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4569436-eli-lilly-bears-making-huge-mistake"
            }
        }
    ]
}